Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | HTR1F | P30939 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378681 | 0.78 | IL1R1 (0.47) | HTR6TAAR1HTR7HTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL9393123 | 0.77 | ALDH1A1 (0.49) | HTR6TAAR1HTR7HTR1DHTR1B | |
| SCHEMBL2758314 | 0.69 | HTR6 (0.45) | HTR6HTR1AHTR7DRD2HTR1D | |
| SCHEMBL14560451 | 0.68 | HTR6 (0.47) | HTR6HTR1AHTR7DRD2HTR1D | |
| SCHEMBL3804671 | 0.67 | HTR6 (0.46) | HTR6HTR7 | |
| SCHEMBL12850609 | 0.67 | HTR2A (0.65) | HTR6HTR1AHTR7DRD2HTR1D | |
| SCHEMBL5095637 | 0.66 | HTR6 (0.57) | HTR6HTR1AHTR7DRD2HTR1D | |
| SCHEMBL17673147 | 0.66 | KDM4E (0.49) | HTR2A | |
| SCHEMBL25294011 | 0.66 | HTR6 (0.69) | HTR6TAAR1HTR1AHTR7DRD2 | |
| SCHEMBL20307301 | 0.66 | HTR6 (0.81) | HTR6HTR1AHTR7DRD2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029010-A1 | METHOD TO USE COMPOSITIONS HAVING ANTIDEPRESSANT ANXIOLYTIC AND OTHER NEUROLOGICAL ACTIVITY AND COMPOSITIONS OF MATTER | HAMANN MARK T (US) | 2012-02-02 | — | — | US | claimed |
| US-20090093513-A1 | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter | HAMANN, MARK T. | 2009-04-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029010-A1 | METHOD TO USE COMPOSITIONS HAVING ANTIDEPRESSANT ANXIOLYTIC AND OTHER NEUROLOGICAL ACTIVITY AND COMPOSITIONS OF MATTER | ACHE, CHAT, HTR3D | HTR6 101/4885TAAR1 1531/4885HTR1A 16/4885 |
| US-20090093513-A1 | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter | ACHE, CHAT, HTR3D | HTR6 101/4885TAAR1 1531/4885HTR1A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.